Adventitial delivery of nanoparticles encapsulated with 1α, 25-dihydroxyvitamin D₃ attenuates restenosis in a murine angioplasty model.

ABSTRACT: Percutaneous transluminal angioplasty (PTA) of stenotic arteriovenous fistulas (AVFs) is performed to maintain optimal function and patency. The one-year patency rate is 60% because of venous neointimal hyperplasia (VNH) and venous stenosis (VS) formation. Immediate early response gene X-1 (Iex-1) also known as Ier3 increases in response to wall shear stress (WSS), and can cause VNH/VS formation in murine AVF. In human stenotic samples from AVFs, we demonstrated increased gene expression of Ier3. We hypothesized that 1α, 25-dihydroxyvitamin D₃, an inhibitor of IER3 delivered as 1α, 25-dihydroxyvitamin D₃ encapsulated in poly lactic-co-glycolic acid (PLGA) nanoparticles loaded in Pluronic F127 hydrogel (1,25 NP) to the adventitia of the stenotic outflow vein after PTA

SUBMITTER: Cai C 

PROVIDER: S-EPMC7910622 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature